This is especially relevant for RASopathies, particularly those caused by activating mutations in H-Ras (Costello syndrome) and K-Ras (Noonan and cardiofaciocutaneous syndromes), which are the most prevalent group of neurodevelopmental disorders (Kim and Baek, 2019; Rauen, 2013; Hebron et al, 2022). The gene discussed is HRAS; the disease is Costello syndrome.